Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1

Highlights • We performed the first in man study with a live replication-deficient delNS1-trivalent vaccine. • Significant antibody titers to influenza strains contained in the vaccine were induced. • Seroconversion occurred most frequently in participants who were seronegative before vaccination. •...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2013-12, Vol.31 (52), p.6194-6200
Hauptverfasser: Mössler, Christina, Groiss, Franz, Wolzt, Michael, Wolschek, Markus, Seipelt, Joachim, Muster, Thomas
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Highlights • We performed the first in man study with a live replication-deficient delNS1-trivalent vaccine. • Significant antibody titers to influenza strains contained in the vaccine were induced. • Seroconversion occurred most frequently in participants who were seronegative before vaccination. • A single intranasal dose was well tolerated and safe in healthy male and female participants. • No vaccine virus could be re-isolated in volunteers after immunization.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2013.10.061